(Q37815281)

23 August 2017

1 reference

title

Biomarkers to predict the clinical efficacy of bevacizumab in cancer (English)

1 reference

23 August 2017

0 references

1 reference

2

1 reference

23 August 2017

Adrian M Jubb

1

1 reference

23 August 2017

1 December 2010

1 reference

Lancet Oncology Commission

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

12

1 reference

23 August 2017

1172-1183

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

23 August 2017

1 reference

7 January 2021

The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Endothelial-specific expression of WNK1 kinase is essential for angiogenesis and heart development in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Characterization and regulation of bv8 in human blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970232-1

7 January 2021

10.1016/S1470-2045(10)70232-1

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21126687